Halozyme Therapeutics Share Price (NASDAQ: HALO)

$72.94

▲

0.13

(0.18%)

Live

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Halozyme Therapeutics Stock chart to analyse performance

Halozyme Therapeutics stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$72.48
Today's High:$73.02
$72.94
0.63%
Downside
Day's Volatility :0.74%
Upside
0.11%
52 Weeks Low:$42.01
52 Weeks High:$74.07
$72.94
42.4%
Downside
52 Weeks Volatility :43.28%
Upside
1.53%

Halozyme Therapeutics Stock Returns

Period	Halozyme Therapeutics, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	29.87%	3.1%	0.0%
6 Months	23.11%	-8.4%	0.0%
1 Year	14.25%	-12.6%	0.0%
3 Years	78.79%	7.9%	-6.1%

Halozyme Therapeutics, Inc. Key Stats

Check Halozyme Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$72.81
Open	$72.98
Today's High	$73.23
Today's Low	$72.48
Market Capitalization	$8.6B
Today's Volume	$1.5M
52 Week High	$74.07
52 Week Low	$42.01
Revenue TTM	$1.2B
EBITDA	$758.6M
Earnings Per Share (EPS)	$4.37
PE Ratio	16.75
Profit Margin	47.28%
Quarterly Earnings Growth YOY	0.85%
Return On Equity TTM	179.14%

Stock Returns calculator for Halozyme Therapeutics Stock including INR - Dollar returns

The Halozyme Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Halozyme Therapeutics investment value today

Current value as on today

₹1,19,753

Returns

₹19,753

(+19.75%)

Returns from Halozyme Therapeutics Stock

₹14,434 (+14.43%)

Dollar Returns*

₹5,319 (+5.32%)

Indian investors sentiment towards Halozyme Therapeutics Stock

307%

Period: Jul 29, 2025 to Aug 28, 2025. Change in 30 Days versus previous period

Search interest for Halozyme Therapeutics Stock from India on INDmoney has increased by 307% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Halozyme Therapeutics, Inc.

Name
Holdings %
Name
Holdings %
BlackRock Inc
14.61%
Vanguard Group Inc
10.47%
State Street Corp
5.18%
Amvescap Plc.
3.33%
Snyder Capital Management LP
2.90%
AllianceBernstein L.P.
2.75%

Analyst Recommendation on Halozyme Therapeutics Stock

Rating

Trend

Buy

82%Buy

17%Hold

0%Sell

Based on 17 Wall street analysts offering stock ratings for Halozyme Therapeutics(by analysts ranked 0 to 5 stars)

Halozyme Therapeutics Share Price Target

What analysts predicted

Downside of 3.27%

Target:

$70.56

Current:

$72.94

Halozyme Therapeutics share price target is $70.56, a slight Downside of 3.27% compared to current price of $72.94 as per analysts' prediction.

Halozyme Therapeutics Stock Insights

Price Movement
In the last 1 month, HALO stock has moved up by 23.3%
Increasing Revenue
Revenue is up for the last 2 quarters, 264.86M → 325.71M (in $), with an average increase of 18.7% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, 118.09M → 165.16M (in $), with an average increase of 28.5% per quarter
HALO vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 57.5% return, outperforming this stock by 43.3%
HALO vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 116.3% return, outperforming this stock by 36.6%
Price to Sales
ForHALO every $1 of sales, investors are willing to pay $7.7, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.8 for every $1 of sales.

Halozyme Therapeutics, Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$196.0M	↑ 29.06%
Net Income	$-72.2M	↓ 10.07%
Net Profit Margin	-36.86%	↑ 16.04%

	FY20	Y/Y Change
Revenue	$267.6M	↑ 36.53%
Net Income	$129.1M	↓ 278.69%
Net Profit Margin	48.24%	↑ 85.1%

	FY21	Y/Y Change
Revenue	$443.3M	↑ 65.67%
Net Income	$402.7M	↑ 211.97%
Net Profit Margin	90.84%	↑ 42.6%

	FY22	Y/Y Change
Revenue	$660.1M	↑ 48.91%
Net Income	$202.1M	↓ 49.81%
Net Profit Margin	30.62%	↓ 60.22%

	FY23	Y/Y Change
Revenue	$829.3M	↑ 25.62%
Net Income	$281.6M	↑ 39.31%
Net Profit Margin	33.96%	↑ 3.34%

	FY24	Y/Y Change
Revenue	$1.0B	↑ 22.44%
Net Income	$444.1M	↑ 57.71%
Net Profit Margin	43.74%	↑ 9.78%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$195.9M	↓ 14.85%
Net Income	$76.8M	↓ 10.03%
Net Profit Margin	39.22%	↑ 2.1%

	Q2 FY24	Q/Q Change
Revenue	$231.4M	↑ 18.11%
Net Income	$93.2M	↑ 21.38%
Net Profit Margin	40.3%	↑ 1.08%

	Q3 FY24	Q/Q Change
Revenue	$290.1M	↑ 25.39%
Net Income	$137.0M	↑ 46.94%
Net Profit Margin	47.23%	↑ 6.93%

	Q4 FY24	Q/Q Change
Revenue	$298.0M	↑ 2.73%
Net Income	$137.0M	↑ 0.0%
Net Profit Margin	45.98%	↓ 1.25%

	Q1 FY25	Q/Q Change
Revenue	$264.9M	↓ 11.12%
Net Income	$118.1M	↓ 13.81%
Net Profit Margin	44.59%	↓ 1.39%

	Q2 FY25	Q/Q Change
Revenue	$325.7M	↑ 22.98%
Net Income	$165.2M	↑ 39.85%
Net Profit Margin	50.71%	↑ 6.12%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$150.4M	↑ 6.15%

	FY20	Y/Y Change
Profit	$224.2M	↑ 49.04%

	FY21	Y/Y Change
Profit	$361.9M	↑ 61.4%

	FY22	Y/Y Change
Profit	$520.8M	↑ 43.91%

	FY23	Y/Y Change
Profit	$636.9M	↑ 22.29%

	FY24	Y/Y Change
Profit	$855.9M	↑ 34.39%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$149.8M	↓ 15.73%

	Q2 FY24	Q/Q Change
Profit	$174.0M	↑ 16.15%

	Q3 FY24	Q/Q Change
Profit	$240.7M	↑ 38.32%

	Q4 FY24	Q/Q Change
Profit	$256.0M	↑ 6.36%

	Q1 FY25	Q/Q Change
Profit	$216.5M	↓ 15.43%

	Q2 FY25	Q/Q Change
Profit	$279.4M	↑ 29.06%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-85.4M	↑ 72.57%
Investing Cash Flow	$-5.5M	↓ 322.58%
Financing Cash Flow	$153.2M	↓ 340.16%

	FY20	Y/Y Change
Operating Cash Flow	$55.5M	↓ 164.92%
Investing Cash Flow	$78.4M	↓ 1512.04%
Financing Cash Flow	$-106.3M	↓ 169.37%

	FY21	Y/Y Change
Operating Cash Flow	$299.4M	↑ 439.98%
Investing Cash Flow	$-406.3M	↓ 618.53%
Financing Cash Flow	$77.9M	↓ 173.26%

	FY22	Y/Y Change
Operating Cash Flow	$240.1M	↓ 19.81%
Investing Cash Flow	$-487.0M	↑ 19.87%
Financing Cash Flow	$362.4M	↑ 365.38%

	FY23	Y/Y Change
Operating Cash Flow	$388.6M	↑ 61.83%
Investing Cash Flow	$-96.9M	↓ 80.1%
Financing Cash Flow	$-408.0M	↓ 212.59%

	FY24	Y/Y Change
Operating Cash Flow	$479.1M	↑ 23.29%
Investing Cash Flow	$-262.7M	↑ 171.1%
Financing Cash Flow	$-218.9M	↓ 46.36%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$129.4M	↑ 26.45%
Investing Cash Flow	$-82.7M	↑ 897.24%
Financing Cash Flow	$-489.0K	↓ 99.8%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$55.8M	↓ 56.89%
Investing Cash Flow	$-42.0M	↓ 49.16%
Financing Cash Flow	$9.5M	↓ 2039.06%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$115.4M	↑ 106.79%
Investing Cash Flow	$-167.5M	↑ 298.4%
Financing Cash Flow	$18.6M	↑ 95.75%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$178.5M	↑ 54.68%
Investing Cash Flow	$29.5M	↓ 117.6%
Financing Cash Flow	$-246.4M	↓ 1427.6%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$154.2M	↓ 13.59%
Investing Cash Flow	$-90.4M	↓ 406.72%
Financing Cash Flow	$-3.3M	↓ 98.65%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$99.7M	↓ 35.35%
Investing Cash Flow	$84.8M	↓ 193.77%
Financing Cash Flow	$-299.0M	↑ 8902.29%

Halozyme Therapeutics Technicals Summary

Sell

Neutral

Buy

Halozyme Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Halozyme Therapeutics, Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Halozyme Therapeutics, Inc.	21.21%	23.11%	14.25%	78.79%	151.15%
Regeneron Pharmaceuticals, Inc.	3.77%	-17.64%	-51.18%	-2.19%	-7.17%
Beone Medicines Ltd	-0.02%	10.33%	51.07%	81.16%	24.14%
Vertex Pharmaceuticals Incorporated	-16.39%	-18.24%	-20.49%	39.42%	40.54%
Alnylam Pharmaceuticals, Inc.	33.05%	83.22%	57.52%	115.32%	240.85%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Halozyme Therapeutics, Inc.	16.75	16.75	-2.5	6.05	1.79	0.21	NA	2.83
Regeneron Pharmaceuticals, Inc.	14.79	14.79	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.69	27.69	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Halozyme Therapeutics, Inc.	Buy	$8.6B	151.15%	16.75	47.28%
Regeneron Pharmaceuticals, Inc.	Buy	$62.2B	-7.17%	14.79	31.37%
Beone Medicines Ltd	NA	$36.8B	24.14%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$99.8B	40.54%	27.69	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.1B	240.85%	NA	-12.96%

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company offers Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; HYQVIA to treat primary immunodeficiency disorders; Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat solid tumors; teriparatide injections; OTREXUP, an SC methotrexate injection for severe active rheumatoid arthritis, severe recalcitrant psoriasis, and active polyarticular juvenile idiopathic arthritis; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. The company has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; and Acumen Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Organization	Halozyme Therapeutics
Employees	350
CEO	Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
Industry	Health Technology

Key Management of Halozyme Therapeutics, Inc.

Name	Title
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.	President, CEO & Director
Ms. Nicole LaBrosse CPA	Senior VP & CFO
Mr. Mark Snyder Esq.	Senior VP, General Counsel, Chief Compliance Officer & nd Secretary
Ms. Cortney Caudill M.B.A.	Chief Operations Officer
Ms. Tram Bui	Head of Investor Relations & Corporate Communications
Ms. Amy Marinne Fox	Chief Human Resources Officer
Dr. Christopher Wahl M.B.A., M.D.	Chief Business Officer
Dr. Charles P. Theuer M.D., Ph.D.	Chief Medical Officer
Mr. Paul Spence	Chief Commercial Officer

Important FAQs about investing in HALO Stock from India :

What is Halozyme Therapeutics share price today?

Halozyme Therapeutics share price today is $72.94 as on August 30, 2025 at 1:29 am IST. Halozyme Therapeutics share today touched a day high of $73.02 and a low of $72.48.

What is the 52 week high and 52 week low for Halozyme Therapeutics share?

Halozyme Therapeutics share touched a 52 week high of $74.07 and a 52 week low of $42.01. Halozyme Therapeutics stock price today i.e. August 30, 2025 at 1:29 am IST is trending at $72.94, lower by 1.53% versus the 52 week high.

How to invest in Halozyme Therapeutics Stock (HALO) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Halozyme Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Halozyme Therapeutics Shares that will get you 0.0206 shares as per Halozyme Therapeutics share price of $72.94 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Halozyme Therapeutics Stock (HALO) from India?

Indian investors can start investing in Halozyme Therapeutics (HALO) shares with as little as ₹88.286 or $1 (as of August 29, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Halozyme Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 29, 2025). Based on Halozyme Therapeutics share’s latest price of $72.94 as on August 30, 2025 at 1:29 am IST, you will get 0.1371 shares of Halozyme Therapeutics. Learn more about fractional shares .

What are the returns that Halozyme Therapeutics has given to Indian investors in the last 5 years?

Halozyme Therapeutics stock has given 151.15% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?